Literature DB >> 7214269

Multiple endocrine neoplasia, type II: a combined surgical and genetic approach to treatment.

M W Partington, W R Ghent, E V Sears, N E Simpson.   

Abstract

A family with multiple endocrine neoplasia, type II living in southeastern Ontario is described. Twenty individuals are known to have had medullary carcinoma of the thyroid, pheochromocytoma or both, the diagnosis of multiple endocrine neoplasia. type II is strongly suspected in five other individuals in the earlier generations. In this family the diseases seems to be transmitted by an autosomal dominant gene. A screening program set up for the family in 1977 has in 2 years identified four asymptomatic individuals (three with medullary carcinoma of the thyroid and one with this carcinoma and a pheochromocytoma). The family background, clinical picture, treatment and some of the problems of the screening program are described.

Entities:  

Mesh:

Year:  1981        PMID: 7214269      PMCID: PMC1705209     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  12 in total

1.  Stimulation tests for diagnosis of medullary thyroid carcinoma.

Authors:  G W Sizemore; V L Go
Journal:  Mayo Clin Proc       Date:  1975-02       Impact factor: 7.616

2.  Possible linear order of genes for endocrine neoplasia type 2, the P red cell antigen and HL-A on chromosome 6.

Authors:  C E Jackson; P M Conneally; G W Sizemore; A H Tashjian
Journal:  Birth Defects Orig Artic Ser       Date:  1976

3.  Detection of medullary thyroid cancer by calcitonin assay in families.

Authors:  C E Jackson; A H Tashjian; M A Block
Journal:  Ann Intern Med       Date:  1973-06       Impact factor: 25.391

4.  A comparison of pentagastrin injection and calcium infusion as provocative agents for the detection of medullary carcinoma of the thyroid.

Authors:  J F Hennessy; S A Wells; D A Ontjes; C W Cooper
Journal:  J Clin Endocrinol Metab       Date:  1974-09       Impact factor: 5.958

5.  Sipple's syndrome: medullary thyroid carcinoma, pheochromocytoma, and parathyroid disease. Studies in a large family. NIH conference.

Authors:  H R Keiser; M A Beaven; J Doppman; S Wells; L M Buja
Journal:  Ann Intern Med       Date:  1973-04       Impact factor: 25.391

6.  Familial medullary carcinoma of the thyroid, adrenal pheochromocytoma and parathyroid hyperplasia. A syndrome of multiple endocrine neoplasia.

Authors:  K D Pearson; S A Wells; H R Keiser
Journal:  Radiology       Date:  1973-05       Impact factor: 11.105

7.  On medullary carcinoma of the thyroid.

Authors:  O Ljungberg
Journal:  Acta Pathol Microbiol Scand Suppl       Date:  1972

8.  Early diagnosis of medullary carcinoma of the thyroid gland by means of calcitonin assay.

Authors:  K E Melvin; H H Miller; A H Tashjian
Journal:  N Engl J Med       Date:  1971-11       Impact factor: 91.245

9.  Immunoassay for human calcitonin. I. Method.

Authors:  L J Deftos
Journal:  Metabolism       Date:  1971-12       Impact factor: 8.694

10.  Calcium infusion and pentagastrin injection in diagnosis of medullary thyroid carcinoma.

Authors:  M Verdy; J P Cholette; J Cantin; A Lacroix; W C Sturtridge
Journal:  Can Med Assoc J       Date:  1978-07-08       Impact factor: 8.262

View more
  3 in total

1.  Exclusion of linkage between the loci for multiple endocrine neoplasia type-2 (MEN-2) and HLA.

Authors:  N E Simpson; J Falk
Journal:  Hum Genet       Date:  1982       Impact factor: 4.132

2.  Linkage analysis of a DNA marker localized to 20p12 and multiple endocrine neoplasia type 2A.

Authors:  P J Goodfellow; B N White; J J Holden; A M Duncan; E V Sears; H S Wang; L Berlin; K K Kidd; N E Simpson
Journal:  Am J Hum Genet       Date:  1985-09       Impact factor: 11.025

3.  The mutation for medullary thyroid carcinoma with parathyroid tumors (MTC with PTs) is closely linked to the centromeric region of chromosome 10.

Authors:  N L Carson; J S Wu; C E Jackson; K K Kidd; N E Simpson
Journal:  Am J Hum Genet       Date:  1990-12       Impact factor: 11.025

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.